Buspirone hydrochloride
Brand names: Buspar (legacy)
Buspirone is a non-benzodiazepine anxiolytic used for the short-term management of generalised anxiety disorder.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It is a partial agonist at 5-HT1A serotonin receptors, modulating serotonergic neurotransmission to produce anxiolysis without significant sedative, muscle-relaxant or dependence-forming effects.
Prescribing in practice
- Its anxiolytic effect develops gradually over weeks, so it is unsuitable for acute anxiety or 'as required' relief and patients should be told not to expect an immediate benefit.
- It does not prevent or treat benzodiazepine withdrawal, so a patient being switched from a benzodiazepine still needs that drug tapered separately.
- Avoid concurrent monoamine oxidase inhibitors and use caution with other serotonergic agents because of the risk of hypertensive or serotonergic reactions.
Monitoring
Monitor anxiety symptom response and tolerability over the first few weeks of treatment.
Counselling the patient
- This medicine takes a couple of weeks to start working, so keep taking it regularly rather than only when anxious.
- Avoid grapefruit juice, which can raise the amount of drug in your body.
- Report severe headache or feeling very agitated.
Evidence & guidelines
Buspirone is an established option for generalised anxiety disorder, distinct from benzodiazepines in lacking dependence liability.
Reference: NICE NG191; NICE CG113; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Acute Behavioural Disturbance / Rapid Tranquillisation · RCEM 2022; RCPsych 2022; NICE NG10
- Self-Harm Presentation · NICE NG225 (2022)
- Capacity Assessment (Mental Capacity Act) · MCA 2005; Code of Practice
- Acute Psychosis Management · NICE CG178 2014
- Depression Management · NICE CG90 2022
- Lithium Therapy Monitoring · NICE CG185